Research Publications

Polzer K, Joosten L, Gasser J, Distler JH, Ruiz G, Baum W, Redlich K, Bobacz K, Smolen JS, van den Berg W, Schett G, Zwerina J. IL-1 is essential for systemic inflammatory bone loss. Ann Rheum Dis. 2009 Feb 5.

Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Jüngel A, Schett G, Distler O, Distler JH. Treatment with imatinib does not only prevent fibrosis in different preclinical models of SSc, but also induces regression of established fibrosis. Arthritis Rheum 2009 Jan;60(1):219-24.

Hanitsch LG, Burmester GR, …, Distler J, …, Riemekasten G. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. Rheumatology (Oxford). 2009 Jan;48(1):70-3.

Venalis P, Maurer B, Akhmetshina A, Busch N, Dees C, Stürzl M, Zwerina J, Jüngel A, Gay S, Schett G, Distler O, Distler JH. Effects of imatinib mesylate on endothelial cell functions in vitro and in vivo. J Cell Mol Med. 2008 Sep 4.